{"transactions":[{"id":789582,"issuer":{"id":4476,"kind":"organization","name":"Hemab Therapeutics Holdings, Inc.","symbol":"COAG"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2026-05-06T20:55:22.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":32695,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":719290},"source":{"system":"sec-edgar","filing":"0001388325-26-000023","document":"form4-05062026_080518.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000138832526000023/form4-05062026_080518.xml","form_type":"4"}},{"id":789581,"issuer":{"id":4476,"kind":"organization","name":"Hemab Therapeutics Holdings, Inc.","symbol":"COAG"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-05-06T20:55:22.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":62121,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1366662},"source":{"system":"sec-edgar","filing":"0001388325-26-000023","document":"form4-05062026_080518.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000138832526000023/form4-05062026_080518.xml","form_type":"4"}},{"id":789580,"issuer":{"id":4476,"kind":"organization","name":"Hemab Therapeutics Holdings, Inc.","symbol":"COAG"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-05-06T20:55:22.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":71866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1581052},"source":{"system":"sec-edgar","filing":"0001388325-26-000023","document":"form4-05062026_080518.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000138832526000023/form4-05062026_080518.xml","form_type":"4"}},{"id":789579,"issuer":{"id":4476,"kind":"organization","name":"Hemab Therapeutics Holdings, Inc.","symbol":"COAG"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2026-05-06T20:55:22.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":23343,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":513546},"source":{"system":"sec-edgar","filing":"0001388325-26-000023","document":"form4-05062026_080518.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000138832526000023/form4-05062026_080518.xml","form_type":"4"}},{"id":789578,"issuer":{"id":4476,"kind":"organization","name":"Hemab Therapeutics Holdings, Inc.","symbol":"COAG"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-06T20:55:22.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":true,"shares":4180550,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date."}],"balance_after":4180550,"source":{"system":"sec-edgar","filing":"0001388325-26-000023","document":"form4-05062026_080518.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000138832526000023/form4-05062026_080518.xml","form_type":"4"}},{"id":791323,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-05-05T20:15:10.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":12558081,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Voting Common Stock","underlying_shares":652649},"source":{"system":"sec-edgar","filing":"0001388325-26-000021","document":"form4-05052026_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000138832526000021/form4-05052026_040501.xml","form_type":"4"}},{"id":791322,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-05-05T20:15:10.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":5587603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Voting Common Stock","underlying_shares":290390},"source":{"system":"sec-edgar","filing":"0001388325-26-000021","document":"form4-05052026_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000138832526000021/form4-05052026_040501.xml","form_type":"4"}},{"id":791321,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-05-05T20:15:10.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":25899284,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Voting Common Stock","underlying_shares":1345997},"source":{"system":"sec-edgar","filing":"0001388325-26-000021","document":"form4-05052026_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000138832526000021/form4-05052026_040501.xml","form_type":"4"}},{"id":791320,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-05-05T20:15:10.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":1986369,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Voting Common Stock","underlying_shares":103232},"source":{"system":"sec-edgar","filing":"0001388325-26-000021","document":"form4-05052026_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000138832526000021/form4-05052026_040501.xml","form_type":"4"}},{"id":791319,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-05-05T20:15:10.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":18000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Voting Common Stock","underlying_shares":935466},"source":{"system":"sec-edgar","filing":"0001388325-26-000021","document":"form4-05052026_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000138832526000021/form4-05052026_040501.xml","form_type":"4"}},{"id":791318,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Voting Common Stock","published_at":"2026-05-05T20:15:10.000Z","date":"2026-05-01","kind":"purchase","planned":false,"acquired":true,"shares":555555,"price":18,"value":9999990.0,"ownership":{"direct":true},"balance_after":3883289,"source":{"system":"sec-edgar","filing":"0001388325-26-000021","document":"form4-05052026_040501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000138832526000021/form4-05052026_040501.xml","form_type":"4"}},{"id":791317,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Voting Common Stock","published_at":"2026-05-05T20:15:10.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":true,"shares":3327734,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date."}],"balance_after":3327734,"source":{"system":"sec-edgar","filing":"0001388325-26-000021","document":"form4-05052026_040501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000138832526000021/form4-05052026_040501.xml","form_type":"4"}},{"id":1011213,"issuer":{"id":5316,"kind":"organization","name":"MapLight Therapeutics, Inc.","symbol":"MPLT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2025-10-30T20:31:43.000Z","date":"2025-10-28","kind":"exercise","planned":false,"acquired":false,"shares":19734671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Voting Common Stock","underlying_shares":1174682},"source":{"system":"sec-edgar","filing":"0001388325-25-000018","document":"form4-10302025_081039.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000138832525000018/form4-10302025_081039.xml","form_type":"4"}},{"id":1011212,"issuer":{"id":5316,"kind":"organization","name":"MapLight Therapeutics, Inc.","symbol":"MPLT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-10-30T20:31:43.000Z","date":"2025-10-28","kind":"exercise","planned":false,"acquired":false,"shares":26191207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Voting Common Stock","underlying_shares":1558999},"source":{"system":"sec-edgar","filing":"0001388325-25-000018","document":"form4-10302025_081039.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000138832525000018/form4-10302025_081039.xml","form_type":"4"}},{"id":1011211,"issuer":{"id":5316,"kind":"organization","name":"MapLight Therapeutics, Inc.","symbol":"MPLT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Voting Common Stock","published_at":"2025-10-30T20:31:43.000Z","date":"2025-10-28","kind":"purchase","planned":false,"acquired":true,"shares":952941,"price":17,"value":16199997.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents a purchase from the underwriters in the Issuer's initial public offering."}],"balance_after":3686622,"source":{"system":"sec-edgar","filing":"0001388325-25-000018","document":"form4-10302025_081039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000138832525000018/form4-10302025_081039.xml","form_type":"4"}},{"id":1011210,"issuer":{"id":5316,"kind":"organization","name":"MapLight Therapeutics, Inc.","symbol":"MPLT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Voting Common Stock","published_at":"2025-10-30T20:31:43.000Z","date":"2025-10-28","kind":"exercise","planned":false,"acquired":true,"shares":2733681,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date."}],"balance_after":2733681,"source":{"system":"sec-edgar","filing":"0001388325-25-000018","document":"form4-10302025_081039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000138832525000018/form4-10302025_081039.xml","form_type":"4"}},{"id":1448145,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-07-27T01:22:20.000Z","date":"2024-07-26","kind":"sale","planned":false,"acquired":false,"shares":23478,"price":1.3113,"value":30786.7014,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.28 to $1.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":4354449,"source":{"system":"sec-edgar","filing":"0000950170-24-087061","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000095017024087061/ownership.xml","form_type":"4"}},{"id":1448144,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-07-27T01:22:20.000Z","date":"2024-07-25","kind":"sale","planned":false,"acquired":false,"shares":51522,"price":1.3264,"value":68338.7808,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.29 to $1.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":4377927,"source":{"system":"sec-edgar","filing":"0000950170-24-087061","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000095017024087061/ownership.xml","form_type":"4"}},{"id":1517710,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-05-15T01:13:16.000Z","date":"2024-05-10","kind":"sale","planned":false,"acquired":false,"shares":658809,"price":1.2181,"value":802495.2429,"ownership":{"direct":true},"balance_after":4429449,"source":{"system":"sec-edgar","filing":"0000950170-24-059965","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000095017024059965/ownership.xml","form_type":"4"}},{"id":1561900,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-03-26T01:45:53.000Z","date":"2024-03-21","kind":"sale","planned":false,"acquired":false,"shares":465021,"price":0.7547,"value":350951.3487,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.71 to $0.7785, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":2550000,"source":{"system":"sec-edgar","filing":"0001209191-24-005075","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919124005075/doc4.xml","form_type":"4"}},{"id":1565993,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-03-21T00:56:02.000Z","date":"2024-03-20","kind":"sale","planned":false,"acquired":false,"shares":359979,"price":0.7336,"value":264080.5944,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7110 to $0.7633, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":3015021,"source":{"system":"sec-edgar","filing":"0001209191-24-005017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919124005017/doc4.xml","form_type":"4"}},{"id":1565992,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-03-21T00:56:02.000Z","date":"2024-03-19","kind":"sale","planned":false,"acquired":false,"shares":593000,"price":0.755,"value":447715.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7105 to $0.7887, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":3375000,"source":{"system":"sec-edgar","filing":"0001209191-24-005017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919124005017/doc4.xml","form_type":"4"}},{"id":1565991,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-03-21T00:56:02.000Z","date":"2024-03-18","kind":"sale","planned":false,"acquired":false,"shares":842020,"price":0.7684,"value":647008.168,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.75 to $0.8004, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":3968000,"source":{"system":"sec-edgar","filing":"0001209191-24-005017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919124005017/doc4.xml","form_type":"4"}},{"id":1572399,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-03-19T01:14:13.000Z","date":"2024-03-14","kind":"sale","planned":false,"acquired":false,"shares":1912316,"price":0.8884,"value":1698901.5344,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.78 to $1.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":4810020,"source":{"system":"sec-edgar","filing":"0001209191-24-004900","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919124004900/doc4.xml","form_type":"4"}},{"id":1640681,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES B-1 PREFERRED STOCK","published_at":"2024-02-16T01:38:42.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":691760,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":691760},"source":{"system":"sec-edgar","filing":"0001209191-24-003423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919124003423/doc4.xml","form_type":"4"}},{"id":1640680,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES B PREFERRED STOCK","published_at":"2024-02-16T01:38:42.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":147415,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":147415},"source":{"system":"sec-edgar","filing":"0001209191-24-003423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919124003423/doc4.xml","form_type":"4"}},{"id":1640679,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-02-16T01:38:42.000Z","date":"2024-02-13","kind":"purchase","planned":false,"acquired":true,"shares":800000,"price":15,"value":12000000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents a purchase from the underwriters in the Issuer's initial public offering."}],"balance_after":1739175,"source":{"system":"sec-edgar","filing":"0001209191-24-003423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919124003423/doc4.xml","form_type":"4"}},{"id":1640678,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-02-16T01:38:42.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":839175,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock and Series B-1 Preferred Stock converted into Common Stock, on a one-for-one basis, automatically upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."}],"balance_after":939175,"source":{"system":"sec-edgar","filing":"0001209191-24-003423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919124003423/doc4.xml","form_type":"4"}},{"id":1640677,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-02-16T01:38:42.000Z","date":"2024-02-09","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":10.25,"value":1025000.0,"ownership":{"direct":true},"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001209191-24-003423","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919124003423/doc4.xml","form_type":"4"}},{"id":1646533,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2024-02-14T02:31:13.000Z","date":"2024-02-09","kind":"sale","planned":false,"acquired":false,"shares":658809,"price":1.5003,"value":988411.1427,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":5088258,"source":{"system":"sec-edgar","filing":"0001209191-24-003303","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000120919124003303/doc4.xml","form_type":"4"}},{"id":1810029,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-08-11T20:31:47.000Z","date":"2023-08-09","kind":"purchase","planned":false,"acquired":true,"shares":2469135,"price":2.025,"value":4999998.375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a combined purchase price of $2.025 for Common Stock and Warrants from Issuer in a private placement."}],"balance_after":2469135,"derivative":{"exercise_price":2.47,"exercise_date":"2023-08-09","expiration_date":"2027-02-09","underlying":"Common Stock","underlying_shares":2469135},"source":{"system":"sec-edgar","filing":"0001209191-23-045444","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000120919123045444/doc4.xml","form_type":"4"}},{"id":1810028,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-11T20:31:47.000Z","date":"2023-08-09","kind":"purchase","planned":false,"acquired":true,"shares":2469135,"price":2.025,"value":4999998.375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a combined purchase price of $2.025 for Common Stock and Warrants from Issuer in a private placement."}],"balance_after":5707467,"source":{"system":"sec-edgar","filing":"0001209191-23-045444","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000120919123045444/doc4.xml","form_type":"4"}},{"id":1825827,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-20T20:01:11.000Z","date":"2023-07-20","kind":"sale","planned":false,"acquired":false,"shares":100000,"price":2.7514,"value":275140.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":3522136,"source":{"system":"sec-edgar","filing":"0001209191-23-042977","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123042977/doc4.xml","form_type":"4"}},{"id":1825826,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-20T20:01:11.000Z","date":"2023-07-19","kind":"sale","planned":false,"acquired":false,"shares":1900,"price":2.7616,"value":5247.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":3622136,"source":{"system":"sec-edgar","filing":"0001209191-23-042977","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123042977/doc4.xml","form_type":"4"}},{"id":1827817,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-18T20:27:47.000Z","date":"2023-07-18","kind":"sale","planned":false,"acquired":false,"shares":6500,"price":2.7574,"value":17923.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.73 to $2.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":3624036,"source":{"system":"sec-edgar","filing":"0001209191-23-042670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123042670/doc4.xml","form_type":"4"}},{"id":1827816,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-18T20:27:47.000Z","date":"2023-07-17","kind":"sale","planned":false,"acquired":false,"shares":21100,"price":2.7488,"value":57999.68,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.74 to $2.7498, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":3630536,"source":{"system":"sec-edgar","filing":"0001209191-23-042670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123042670/doc4.xml","form_type":"4"}},{"id":1827815,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-18T20:27:47.000Z","date":"2023-07-14","kind":"sale","planned":false,"acquired":false,"shares":11000,"price":2.7365,"value":30101.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.73 to $2.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":3651636,"source":{"system":"sec-edgar","filing":"0001209191-23-042670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123042670/doc4.xml","form_type":"4"}},{"id":1839664,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-03T18:29:46.000Z","date":"2023-06-30","kind":"sale","planned":false,"acquired":false,"shares":200937,"price":2.6341,"value":529288.1517,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.61 to $2.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":3662636,"source":{"system":"sec-edgar","filing":"0001209191-23-040691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123040691/doc4.xml","form_type":"4"}},{"id":1842683,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-28T21:35:43.000Z","date":"2023-06-27","kind":"sale","planned":false,"acquired":false,"shares":31978,"price":1.7727,"value":56687.4006,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.67 to $1.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":3863573,"source":{"system":"sec-edgar","filing":"0001209191-23-040129","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123040129/doc4.xml","form_type":"4"}},{"id":1842682,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-28T21:35:43.000Z","date":"2023-06-26","kind":"sale","planned":false,"acquired":false,"shares":8437,"price":1.7905,"value":15106.4485,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.70 to $1.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":3895551,"source":{"system":"sec-edgar","filing":"0001209191-23-040129","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123040129/doc4.xml","form_type":"4"}},{"id":1842768,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-28T21:04:19.000Z","date":"2023-06-28","kind":"sale","planned":false,"acquired":false,"shares":1250000,"price":46.1,"value":57625000.0,"ownership":{"direct":true},"balance_after":1090772,"source":{"system":"sec-edgar","filing":"0001209191-23-040057","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000120919123040057/doc4.xml","form_type":"4"}},{"id":1844935,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T23:15:12.000Z","date":"2023-06-23","kind":"sale","planned":false,"acquired":false,"shares":100000,"price":7.0974,"value":709740.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.93 to $7.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":3330337,"source":{"system":"sec-edgar","filing":"0001209191-23-039541","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919123039541/doc4.xml","form_type":"4"}},{"id":1845199,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T19:17:26.000Z","date":"2023-06-23","kind":"sale","planned":false,"acquired":false,"shares":3423,"price":1.8834,"value":6446.8782,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.86 to $1.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":3903988,"source":{"system":"sec-edgar","filing":"0001209191-23-039545","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123039545/doc4.xml","form_type":"4"}},{"id":1845198,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T19:17:26.000Z","date":"2023-06-22","kind":"sale","planned":false,"acquired":false,"shares":5041,"price":1.9406,"value":9782.5646,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90 to $2.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":3907411,"source":{"system":"sec-edgar","filing":"0001209191-23-039545","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123039545/doc4.xml","form_type":"4"}},{"id":1845197,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T19:17:26.000Z","date":"2023-06-21","kind":"sale","planned":false,"acquired":false,"shares":4834,"price":1.9944,"value":9640.9296,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.98 to $2.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":3912452,"source":{"system":"sec-edgar","filing":"0001209191-23-039545","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123039545/doc4.xml","form_type":"4"}},{"id":1849554,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-20T17:53:44.000Z","date":"2023-06-20","kind":"sale","planned":false,"acquired":false,"shares":744,"price":2.1145,"value":1573.188,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.1036 to $2.1223, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":3917286,"source":{"system":"sec-edgar","filing":"0001209191-23-038567","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123038567/doc4.xml","form_type":"4"}},{"id":1849553,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-20T17:53:44.000Z","date":"2023-06-16","kind":"sale","planned":false,"acquired":false,"shares":5983,"price":2.0294,"value":12141.9002,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.98 to $2.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":3918030,"source":{"system":"sec-edgar","filing":"0001209191-23-038567","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123038567/doc4.xml","form_type":"4"}},{"id":1849552,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-20T17:53:44.000Z","date":"2023-06-15","kind":"sale","planned":false,"acquired":false,"shares":10002,"price":2.03,"value":20304.06,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.00 to $2.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":3924013,"source":{"system":"sec-edgar","filing":"0001209191-23-038567","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123038567/doc4.xml","form_type":"4"}},{"id":1855907,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-14T20:18:05.000Z","date":"2023-06-14","kind":"sale","planned":false,"acquired":false,"shares":2872,"price":2.1066,"value":6050.1552,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.03 to $2.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":3934015,"source":{"system":"sec-edgar","filing":"0001209191-23-037208","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123037208/doc4.xml","form_type":"4"}},{"id":1855906,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-14T20:18:05.000Z","date":"2023-06-13","kind":"sale","planned":false,"acquired":false,"shares":2626,"price":2.1,"value":5514.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.06 to $2.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":3936887,"source":{"system":"sec-edgar","filing":"0001209191-23-037208","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123037208/doc4.xml","form_type":"4"}},{"id":1855905,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-14T20:18:05.000Z","date":"2023-06-12","kind":"sale","planned":false,"acquired":false,"shares":900,"price":2.0645,"value":1858.05,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.03 to $2.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":3939513,"source":{"system":"sec-edgar","filing":"0001209191-23-037208","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919123037208/doc4.xml","form_type":"4"}},{"id":2003523,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-02-21T21:19:36.000Z","date":"2023-02-16","kind":"purchase","acquired":true,"shares":1656000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the combined purchase price of $3.17 for Common Stock and Warrants acquired from Issuer in a private offering."}],"balance_after":1656000,"derivative":{"exercise_price":3.96,"exercise_date":"2023-02-16","expiration_date":"2028-02-16","underlying":"Common Stock","underlying_shares":1656000},"source":{"system":"sec-edgar","filing":"0001209191-23-011156","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919123011156/doc4.xml","form_type":"4"}},{"id":2003522,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2023-02-21T21:19:36.000Z","date":"2023-02-16","kind":"purchase","acquired":true,"shares":2208000,"price":3.17,"value":6999360.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the combined purchase price of $3.17 for Common Stock and Warrants acquired from Issuer in a private offering."}],"balance_after":6722336,"source":{"system":"sec-edgar","filing":"0001209191-23-011156","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919123011156/doc4.xml","form_type":"4"}},{"id":2157398,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2022-09-16T18:35:28.000Z","date":"2022-09-14","kind":"purchase","acquired":true,"shares":484496,"price":10.32,"value":4999998.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a purchase from the underwriters in the Issuer's public offering."}],"balance_after":6071703,"source":{"system":"sec-edgar","filing":"0001209191-22-050258","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000120919122050258/doc4.xml","form_type":"4"}},{"id":2203310,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2022-07-22T18:52:33.000Z","date":"2022-07-20","kind":"sale","acquired":false,"shares":900000,"price":3,"value":2700000.0,"ownership":{"direct":true},"balance_after":3940413,"source":{"system":"sec-edgar","filing":"0001209191-22-043049","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919122043049/doc4.xml","form_type":"4"}},{"id":2206981,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2022-07-15T20:16:46.000Z","date":"2022-07-13","kind":"sale","acquired":false,"shares":800000,"price":2,"value":1600000.0,"ownership":{"direct":true},"balance_after":3703991,"source":{"system":"sec-edgar","filing":"0001209191-22-042241","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919122042241/doc4.xml","form_type":"4"}},{"id":2371526,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-25T23:21:41.000Z","date":"2022-02-25","kind":"sale","acquired":false,"shares":300,"price":2.7032,"value":810.96,"ownership":{"direct":true},"balance_after":2161990,"source":{"system":"sec-edgar","filing":"0001209191-22-013316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919122013316/doc4.xml","form_type":"4"}},{"id":2371525,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-25T23:21:41.000Z","date":"2022-02-24","kind":"sale","acquired":false,"shares":5990,"price":2.8345,"value":16978.655,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.79 to $2.91. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price noted in this footnote."}],"balance_after":2162290,"source":{"system":"sec-edgar","filing":"0001209191-22-013316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919122013316/doc4.xml","form_type":"4"}},{"id":2371524,"issuer":{"id":126718,"kind":"organization","name":"Checkmate Pharmaceuticals, Inc.","symbol":"CMPI"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-25T23:21:41.000Z","date":"2022-02-23","kind":"sale","acquired":false,"shares":1820,"price":2.8997,"value":5277.454,"ownership":{"direct":true},"balance_after":2168280,"source":{"system":"sec-edgar","filing":"0001209191-22-013316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919122013316/doc4.xml","form_type":"4"}},{"id":2406055,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES C PREFERRED STOCK","published_at":"2022-02-09T22:42:27.000Z","date":"2022-02-08","kind":"exercise","acquired":false,"shares":433196,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":433196},"source":{"system":"sec-edgar","filing":"0001209191-22-008145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919122008145/doc4.xml","form_type":"4"}},{"id":2406054,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES B-2 PREFERRED STOCK","published_at":"2022-02-09T22:42:27.000Z","date":"2022-02-08","kind":"exercise","acquired":false,"shares":533389,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":533389},"source":{"system":"sec-edgar","filing":"0001209191-22-008145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919122008145/doc4.xml","form_type":"4"}},{"id":2406053,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES B-1 PREFERRED STOCK","published_at":"2022-02-09T22:42:27.000Z","date":"2022-02-08","kind":"exercise","acquired":false,"shares":666651,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":666651},"source":{"system":"sec-edgar","filing":"0001209191-22-008145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919122008145/doc4.xml","form_type":"4"}},{"id":2406052,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES A PREFERRED STOCK","published_at":"2022-02-09T22:42:27.000Z","date":"2022-02-08","kind":"exercise","acquired":false,"shares":1550309,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":1550309},"source":{"system":"sec-edgar","filing":"0001209191-22-008145","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919122008145/doc4.xml","form_type":"4"}},{"id":2406051,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2022-02-09T22:42:27.000Z","date":"2022-02-08","kind":"purchase","acquired":true,"shares":833333,"price":15,"value":12499995.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a purchase from the underwriters in the Issuer's initial public offering."}],"balance_after":4016878,"source":{"system":"sec-edgar","filing":"0001209191-22-008145","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919122008145/doc4.xml","form_type":"4"}},{"id":2406050,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2022-02-09T22:42:27.000Z","date":"2022-02-08","kind":"exercise","acquired":true,"shares":3183545,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, and Series C Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":3183545,"source":{"system":"sec-edgar","filing":"0001209191-22-008145","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919122008145/doc4.xml","form_type":"4"}},{"id":2518068,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES C CONVERTIBLE PREFERRED STOCK","published_at":"2021-11-11T00:04:50.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":75267,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":946217},"source":{"system":"sec-edgar","filing":"0001209191-21-063969","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000120919121063969/doc4.xml","form_type":"4"}},{"id":2518067,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES B CONVERTIBLE PREFERRED STOCK","published_at":"2021-11-11T00:04:50.000Z","date":"2021-11-09","kind":"exercise","acquired":false,"shares":217107,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":2006715},"source":{"system":"sec-edgar","filing":"0001209191-21-063969","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000120919121063969/doc4.xml","form_type":"4"}},{"id":2518066,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-11-11T00:04:50.000Z","date":"2021-11-09","kind":"purchase","acquired":true,"shares":325000,"price":14,"value":4550000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a purchase from the underwriters in the Issuer's initial public offering."}],"balance_after":3277932,"source":{"system":"sec-edgar","filing":"0001209191-21-063969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000120919121063969/doc4.xml","form_type":"4"}},{"id":2518065,"issuer":{"id":8764,"kind":"organization","name":"IO Biotech, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-11-11T00:04:50.000Z","date":"2021-11-09","kind":"exercise","acquired":true,"shares":2952932,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock converted to common stock based on a conversion ratio that took into account interest that accrued since the date of issuance of the preferred stock and the price of the common stock sold to the underwriters in the IPO."}],"balance_after":2952932,"source":{"system":"sec-edgar","filing":"0001209191-21-063969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865494/000120919121063969/doc4.xml","form_type":"4"}},{"id":2533539,"issuer":{"id":115564,"kind":"organization","name":"MINERVA SURGICAL INC","symbol":"UTRS"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SUBORDINATED SECURED CONVERTIBLE PROMISSORY NOTES","published_at":"2021-10-27T16:31:14.000Z","date":"2021-10-26","kind":"exercise","acquired":false,"reported_value":5550060,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Subordinated Secured Convertible Promissory Notes converted into preferred stock, which converts into common stock on a 1-for-1 basis into the number of shares of common stock as shown in Column 7, which gives effect to the issuer's reverse stock split effected October 14, 2021, automatically upon the closing of the Issuer's IPO without payment of further consideration. The notes have a maturity date of June 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Subordinated Secured Convertible Promissory Notes converted into preferred stock, which converts into common stock on a 1-for-1 basis into the number of shares of common stock as shown in Column 7, which gives effect to the issuer's reverse stock split effected October 14, 2021, automatically upon the closing of the Issuer's IPO without payment of further consideration. The notes have a maturity date of June 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Subordinated Secured Convertible Promissory Notes converted into preferred stock, which converts into common stock on a 1-for-1 basis into the number of shares of common stock as shown in Column 7, which gives effect to the issuer's reverse stock split effected October 14, 2021, automatically upon the closing of the Issuer's IPO without payment of further consideration. The notes have a maturity date of June 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Subordinated Secured Convertible Promissory Notes converted into preferred stock, which converts into common stock on a 1-for-1 basis into the number of shares of common stock as shown in Column 7, which gives effect to the issuer's reverse stock split effected October 14, 2021, automatically upon the closing of the Issuer's IPO without payment of further consideration. The notes have a maturity date of June 30, 2023."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":592648},"source":{"system":"sec-edgar","filing":"0001209191-21-061795","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1452965/000120919121061795/doc4.xml","form_type":"4"}},{"id":2533538,"issuer":{"id":115564,"kind":"organization","name":"MINERVA SURGICAL INC","symbol":"UTRS"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES D REDEEMABLE CONVERTIBLE PREFERRED STOCK","published_at":"2021-10-27T16:31:14.000Z","date":"2021-10-26","kind":"exercise","acquired":false,"shares":884484,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D Redeemable Convertible Preferred Stock converted into common stock on a 1-for-1 basis into the number of shares of common stock as shown in Column 7, which gives effect to the issuer's reverse stock split effected October 14, 2021, automatically upon the closing of the Issuer's initial public offering (\"IPO\") without payment of further consideration. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series D Redeemable Convertible Preferred Stock converted into common stock on a 1-for-1 basis into the number of shares of common stock as shown in Column 7, which gives effect to the issuer's reverse stock split effected October 14, 2021, automatically upon the closing of the Issuer's initial public offering (\"IPO\") without payment of further consideration. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D Redeemable Convertible Preferred Stock converted into common stock on a 1-for-1 basis into the number of shares of common stock as shown in Column 7, which gives effect to the issuer's reverse stock split effected October 14, 2021, automatically upon the closing of the Issuer's initial public offering (\"IPO\") without payment of further consideration. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D Redeemable Convertible Preferred Stock converted into common stock on a 1-for-1 basis into the number of shares of common stock as shown in Column 7, which gives effect to the issuer's reverse stock split effected October 14, 2021, automatically upon the closing of the Issuer's initial public offering (\"IPO\") without payment of further consideration. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":884484},"source":{"system":"sec-edgar","filing":"0001209191-21-061795","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1452965/000120919121061795/doc4.xml","form_type":"4"}},{"id":2533537,"issuer":{"id":115564,"kind":"organization","name":"MINERVA SURGICAL INC","symbol":"UTRS"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-10-27T16:31:14.000Z","date":"2021-10-26","kind":"purchase","acquired":true,"shares":580000,"price":12,"value":6960000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a purchase from the underwriters in the Issuer's IPO."}],"balance_after":2057132,"source":{"system":"sec-edgar","filing":"0001209191-21-061795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1452965/000120919121061795/doc4.xml","form_type":"4"}},{"id":2533536,"issuer":{"id":115564,"kind":"organization","name":"MINERVA SURGICAL INC","symbol":"UTRS"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-10-27T16:31:14.000Z","date":"2021-10-26","kind":"exercise","acquired":true,"shares":592648,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Subordinated Secured Convertible Promissory Notes converted into preferred stock, which converts into common stock on a 1-for-1 basis into the number of shares of common stock as shown in Column 7, which gives effect to the issuer's reverse stock split effected October 14, 2021, automatically upon the closing of the Issuer's IPO without payment of further consideration. The notes have a maturity date of June 30, 2023."}],"balance_after":1477132,"source":{"system":"sec-edgar","filing":"0001209191-21-061795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1452965/000120919121061795/doc4.xml","form_type":"4"}},{"id":2533535,"issuer":{"id":115564,"kind":"organization","name":"MINERVA SURGICAL INC","symbol":"UTRS"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-10-27T16:31:14.000Z","date":"2021-10-26","kind":"exercise","acquired":true,"shares":884484,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series D Redeemable Convertible Preferred Stock converted into common stock on a 1-for-1 basis into the number of shares of common stock as shown in Column 7, which gives effect to the issuer's reverse stock split effected October 14, 2021, automatically upon the closing of the Issuer's initial public offering (\"IPO\") without payment of further consideration. These shares have no expiration date."}],"balance_after":884484,"source":{"system":"sec-edgar","filing":"0001209191-21-061795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1452965/000120919121061795/doc4.xml","form_type":"4"}},{"id":2657107,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES C CONVERTIBLE PREFERRED STOCK","published_at":"2021-06-23T17:18:29.000Z","date":"2021-06-22","kind":"exercise","acquired":false,"shares":1553116,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of common stock, based on a conversion ratio of 1 share of preferred stock for 0.2934 shares of common stock, upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of common stock, based on a conversion ratio of 1 share of preferred stock for 0.2934 shares of common stock, upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of common stock, based on a conversion ratio of 1 share of preferred stock for 0.2934 shares of common stock, upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of common stock, based on a conversion ratio of 1 share of preferred stock for 0.2934 shares of common stock, upon the completion of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":455619},"source":{"system":"sec-edgar","filing":"0001209191-21-042786","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919121042786/doc4.xml","form_type":"4"}},{"id":2657106,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES B CONVERTIBLE PREFERRED STOCK","published_at":"2021-06-23T17:18:29.000Z","date":"2021-06-22","kind":"exercise","acquired":false,"shares":14000000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of common stock, based on a conversion ratio of 1 share of preferred stock for 0.2934 shares of common stock, upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of common stock, based on a conversion ratio of 1 share of preferred stock for 0.2934 shares of common stock, upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of common stock, based on a conversion ratio of 1 share of preferred stock for 0.2934 shares of common stock, upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of common stock, based on a conversion ratio of 1 share of preferred stock for 0.2934 shares of common stock, upon the completion of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":4107017},"source":{"system":"sec-edgar","filing":"0001209191-21-042786","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919121042786/doc4.xml","form_type":"4"}},{"id":2657105,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-06-23T17:18:29.000Z","date":"2021-06-22","kind":"purchase","acquired":true,"shares":277777,"price":18,"value":4999986.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a purchase from the underwriters in the Issuer's initial public offering."}],"balance_after":4840413,"source":{"system":"sec-edgar","filing":"0001209191-21-042786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919121042786/doc4.xml","form_type":"4"}},{"id":2657104,"issuer":{"id":92707,"kind":"organization","name":"Cyteir Therapeutics, Inc.","symbol":"CYT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-06-23T17:18:29.000Z","date":"2021-06-22","kind":"exercise","acquired":true,"shares":4562636,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of common stock, based on a conversion ratio of 1 share of preferred stock for 0.2934 shares of common stock, upon the completion of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":4562636,"source":{"system":"sec-edgar","filing":"0001209191-21-042786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662244/000120919121042786/doc4.xml","form_type":"4"}},{"id":2659194,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES B CONVERTIBLE PREFERRED STOCK","published_at":"2021-06-22T17:17:32.000Z","date":"2021-06-21","kind":"exercise","acquired":false,"shares":443265,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":443265},"source":{"system":"sec-edgar","filing":"0001209191-21-042452","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000120919121042452/doc4.xml","form_type":"4"}},{"id":2659193,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-06-22T17:17:32.000Z","date":"2021-06-21","kind":"purchase","acquired":true,"shares":350000,"price":19,"value":6650000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a purchase from the underwriters in the Issuer's initial public offering."}],"balance_after":793265,"source":{"system":"sec-edgar","filing":"0001209191-21-042452","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000120919121042452/doc4.xml","form_type":"4"}},{"id":2659192,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-06-22T17:17:32.000Z","date":"2021-06-21","kind":"exercise","acquired":true,"shares":443265,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":443265,"source":{"system":"sec-edgar","filing":"0001209191-21-042452","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000120919121042452/doc4.xml","form_type":"4"}},{"id":2682896,"issuer":{"id":2083,"kind":"organization","name":"Inogen Inc","symbol":"INGN"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-06-03T23:21:48.000Z","date":"2021-06-02","kind":"sale","acquired":false,"shares":680000,"price":57.32,"value":38977600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were sold as a block sale broker transaction."}],"balance_after":2079320,"source":{"system":"sec-edgar","filing":"0001209191-21-037932","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294133/000120919121037932/doc4.xml","form_type":"4"}},{"id":2700948,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-05-21T20:32:39.000Z","date":"2021-05-19","kind":"sale","acquired":false,"shares":475000,"price":13.9,"value":6602500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The securities were sold as a block sale broker transaction."}],"balance_after":4514336,"source":{"system":"sec-edgar","filing":"0001209191-21-034923","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919121034923/doc4.xml","form_type":"4"}},{"id":2749343,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES B CONVERTIBLE PREFERRED STOCK","published_at":"2021-04-14T20:44:46.000Z","date":"2021-04-13","kind":"exercise","acquired":false,"shares":12367054,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Convertible Preferred Stock converted into common stock at a ratio of 1:4.47848 into the number of shares of common stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Preferred Stock converted into common stock at a ratio of 1:4.47848 into the number of shares of common stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock converted into common stock at a ratio of 1:4.47848 into the number of shares of common stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock converted into common stock at a ratio of 1:4.47848 into the number of shares of common stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":2763711},"source":{"system":"sec-edgar","filing":"0001209191-21-026667","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919121026667/doc4.xml","form_type":"4"}},{"id":2749342,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-04-14T20:44:46.000Z","date":"2021-04-13","kind":"purchase","acquired":true,"shares":666666,"price":15,"value":9999990.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents a purchase from the underwriters in the Issuer's initial public offering."}],"balance_after":3430377,"source":{"system":"sec-edgar","filing":"0001209191-21-026667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919121026667/doc4.xml","form_type":"4"}},{"id":2749341,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-04-14T20:44:46.000Z","date":"2021-04-13","kind":"exercise","acquired":true,"shares":2763711,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Preferred Stock converted into common stock at a ratio of 1:4.47848 into the number of shares of common stock as shown in Column 7 upon the closing of the Issuer's initial public offering without payment of additional consideration. These shares have no expiration date."}],"balance_after":2763711,"source":{"system":"sec-edgar","filing":"0001209191-21-026667","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919121026667/doc4.xml","form_type":"4"}},{"id":2766482,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES C CONVERTIBLE PREFERRED STOCK","published_at":"2021-03-31T20:36:05.000Z","date":"2021-03-30","kind":"exercise","acquired":false,"shares":650328,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B-1 Convertible Preferred Stock, Series B-2 Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Convertible Preferred Stock, Series B-2 Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B-1 Convertible Preferred Stock, Series B-2 Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B-1 Convertible Preferred Stock, Series B-2 Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":650328},"source":{"system":"sec-edgar","filing":"0001209191-21-023779","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000120919121023779/doc4.xml","form_type":"4"}},{"id":2766481,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES B-2 CONVERTIBLE PREFERRED STOCK","published_at":"2021-03-31T20:36:05.000Z","date":"2021-03-30","kind":"exercise","acquired":false,"shares":1952439,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B-1 Convertible Preferred Stock, Series B-2 Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Convertible Preferred Stock, Series B-2 Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B-1 Convertible Preferred Stock, Series B-2 Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B-1 Convertible Preferred Stock, Series B-2 Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":1952439},"source":{"system":"sec-edgar","filing":"0001209191-21-023779","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000120919121023779/doc4.xml","form_type":"4"}},{"id":2766480,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES B-1 CONVERTIBLE PREFERRED STOCK","published_at":"2021-03-31T20:36:05.000Z","date":"2021-03-30","kind":"exercise","acquired":false,"shares":2359440,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B-1 Convertible Preferred Stock, Series B-2 Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Convertible Preferred Stock, Series B-2 Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B-1 Convertible Preferred Stock, Series B-2 Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B-1 Convertible Preferred Stock, Series B-2 Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":2359440},"source":{"system":"sec-edgar","filing":"0001209191-21-023779","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000120919121023779/doc4.xml","form_type":"4"}},{"id":2766479,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-03-31T20:36:05.000Z","date":"2021-03-30","kind":"purchase","acquired":true,"shares":625000,"price":16,"value":10000000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a purchase from the underwriters in the Issuer's initial public offering."}],"balance_after":5587207,"source":{"system":"sec-edgar","filing":"0001209191-21-023779","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000120919121023779/doc4.xml","form_type":"4"}},{"id":2766478,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-03-31T20:36:05.000Z","date":"2021-03-30","kind":"exercise","acquired":true,"shares":4962207,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Convertible Preferred Stock, Series B-2 Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":4962207,"source":{"system":"sec-edgar","filing":"0001209191-21-023779","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000120919121023779/doc4.xml","form_type":"4"}},{"id":2812468,"issuer":{"id":2083,"kind":"organization","name":"Inogen Inc","symbol":"INGN"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-03-03T21:33:34.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":790000,"price":49,"value":38710000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The securities were sold as a block sale broker transaction."}],"balance_after":2759320,"source":{"system":"sec-edgar","filing":"0001209191-21-016876","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294133/000120919121016876/doc4.xml","form_type":"4"}},{"id":2845669,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-02-19T22:20:10.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":500000,"price":10.58,"value":5290000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The securities were sold as a block sale broker transaction."}],"balance_after":2459021,"source":{"system":"sec-edgar","filing":"0001209191-21-012452","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388325/000120919121012452/doc4.xml","form_type":"4"}},{"id":2866670,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES C-2 PREFERRED STOCK","published_at":"2021-02-11T21:39:52.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":458337,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":458337},"source":{"system":"sec-edgar","filing":"0001209191-21-009720","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121009720/doc4.xml","form_type":"4"}},{"id":2866669,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES C-1 PREFERRED STOCK","published_at":"2021-02-11T21:39:52.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":421670,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":421670},"source":{"system":"sec-edgar","filing":"0001209191-21-009720","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121009720/doc4.xml","form_type":"4"}},{"id":2866668,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES B PREFERRED STOCK","published_at":"2021-02-11T21:39:52.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":2050758,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":2050758},"source":{"system":"sec-edgar","filing":"0001209191-21-009720","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121009720/doc4.xml","form_type":"4"}},{"id":2866667,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"SERIES A-1 PREFERRED STOCK","published_at":"2021-02-11T21:39:52.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":1096323,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":1096323},"source":{"system":"sec-edgar","filing":"0001209191-21-009720","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121009720/doc4.xml","form_type":"4"}},{"id":2866666,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-02-11T21:39:52.000Z","date":"2021-02-09","kind":"purchase","acquired":true,"shares":400000,"price":20,"value":8000000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a purchase from the underwriters in the Issuer's initial public offering."}],"balance_after":4503991,"source":{"system":"sec-edgar","filing":"0001209191-21-009720","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121009720/doc4.xml","form_type":"4"}},{"id":2866665,"issuer":{"id":8082,"kind":"organization","name":"Bolt Biotherapeutics, Inc.","symbol":"BOLT"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-02-11T21:39:52.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":4027088,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-1 Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date."}],"balance_after":4103991,"source":{"system":"sec-edgar","filing":"0001209191-21-009720","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1641281/000120919121009720/doc4.xml","form_type":"4"}},{"id":2888725,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":49339,"kind":"organization","name":"NOVO HOLDINGS A/S","position":1,"cik":"0001388325","reported_name":"Novo Holdings A/S","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK","published_at":"2021-02-01T16:30:51.000Z","date":"2021-01-28","kind":"sale","acquired":false,"shares":375000,"price":21,"value":7875000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The securities were sold as a block sale broker transaction."}],"balance_after":2194379,"source":{"system":"sec-edgar","filing":"0001209191-21-006446","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000120919121006446/doc4.xml","form_type":"4"}}],"next_cursor":"2021-02-01T16:30:51.000000Z,2888725"}